Seminar on Evidence in Action

Date: 1 October 2018
Venue: Monash University Malaysia

Program Overview

The seminar aims to provide an understanding of Health Technology Assessment (HTA) and how it can be utilized in various areas. Hepatitis C is used as an example, not just of HTA but also to illustrate issues related to access to medicines globally.

HTA is an evidence-based, multidisciplinary process intended to support healthcare decision making by assessing properties and effects of one or more new or existing health technologies in comparison with a current standard. It can also provide input into policymaking. Aiming at determining added value, HTA uses explicit analytical frameworks based on research and the scientific method in a systematic, transparent, unbiased way.

This seminar will cover the basics of HTA, elaborating on what it is, the areas that are usually focused on, and the work process involved. This will be followed by a historical overview, indicating how from the Office of Technology Assessment in the US, it has been adopted all over the world. Following the global overview, an account will be provided of the beginnings of HTA in Malaysia and the successes that it has had. Examples will then be provided of how HTA has been used all over the world in policy formulation and decision making including purchasing decisions, determination of benefits packages in healthcare financing and the like.   The final session will cover case studies from various areas countries including Hepatitis C which has a large disease burden, and where there are effective drugs which are unfortunately very expensive so that many countries cannot afford the treatment. The morning will be rounded off with a panel discussion on the topics covered, as well as to cater to discussions from the floor.

The second part of the seminar delves further into illustrating the problems with Hepatitis C treatment. There will be an introduction to intellectual property and drugs, patents and monopoly pricing, and the World Trade Organization. AIDS/HIV and Hepatitis C will be used to illustrate the problems, the consequences, and how the problems were eventually overcome in some countries.  The work of Malaysian research in the development of Ravidasvir, an affordable antiviral for the treatment of Hepatitis C, that is currently undergoing Phase III trials in Thailand and Malaysia, will be described along with role of Drugs for Neglected Diseases Initiative. The final session for the afternoon will be a description of the experience of the Third World Network in its efforts towards compulsory licensing for Sofosbuvir, a drug for treating Hepatitis C. There will again be a panel discussion on areas related to the topics covered.

Who should attend?

Medical and surgical specialists, pharmacists, general practitioners, medical and health officers, policy makers, and other healthcare professionals.

This seminar has been approved for 8 MMA-CPD points.

Speaker's Profiles

Program Schedule

Registration Fee

RM 250 (inclusive of lunch and tea breaks)

Payment Methods

1) Bank Transfer / Direct Bank in / Telegraphic Transfer

Payee Name: Monash University Malaysia Sdn Bhd
Bank Name: Public Bank Berhad
Account No.: 307 412 960 5

2) Credit Card
http://finapps.monash.edu.my/ebpg/online_payment.php

Please register online and email the payment slip to Ms. Camelia Marsha Minjoot at camelia.marsha@monash.edu

.

Contact

For further information, please contact: